Physician profile
Steven Sieber
NPI 1942224043
$1,434.98
in general payments reported to CMS, 2019-2025
29 companies · $31.19 in 2025
The $31.19 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $255 · 2023: $105 · 2025: $31.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $186.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.86 | 2019-2023 | Keytruda |
| Sanofi-Aventis U.S. LLC | $73.51 | 2019 | |
| Amag Pharmaceuticals, INC. | $71.67 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $71.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.87 | 2019-2020 | |
| Puma Biotechnology, INC. | $56.78 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $55.89 | 2019-2020 | |
| Exelixis INC. | $55.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.47 | 2019-2020 | |
| Clovis Oncology, INC. | $49.09 | 2019 | |
| Amgen INC. | $43.95 | 2019 | |
| Tesaro, INC. | $43.54 | 2019 | |
| Novocure INC. | $40.79 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $40.78 | 2019 | |
| Eisai INC. | $36.34 | 2019 | |
| Seagen INC. | $35.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.56 | 2019 | |
| Array Biopharma INC | $32.88 | 2019 | |
| Caris Mpi, INC. | $31.19 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $27.07 | 2019 | |
| Taiho Oncology, INC. | $24.82 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.51 | 2019 | |
| Abbvie INC. | $16.15 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.60 | 2019 | |
| Daiichi Sankyo INC. | $13.37 | 2019 | |
| Incyte Corporation | $12.14 | 2019 | |
| Emd Serono, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.